Skip to main content
. Author manuscript; available in PMC: 2025 May 1.
Published in final edited form as: Neuropharmacology. 2024 Feb 6;248:109851. doi: 10.1016/j.neuropharm.2024.109851

Fig. 2. Females exhibited higher %RC relative to males at baseline in the RPT.

Fig. 2.

The number of rats within each %RC category revealed that females were more risk-prone and less risk-averse than males (A). Overall, females exhibited higher %RC than males (B). Mean choice (C) and reward (D) latencies did not differ by sex. Females completed less trials than males (E). In-terms of decision-making metrics, %safe-stay trials were lower in females (F), while %risk-lose stay trials (G) and % risky-win stay trials (H) were higher in females. Data presented as individual data-points, plus mean ± S.E.M., * = p < 0.05 as indicated.